|
|
|
|
|
by mft_
20 days ago
|
|
Your numbers are a little off. The NEJM article was published a few hours ago: https://www.nejm.org/doi/full/10.1056/NEJMoa2605555 RAS G12 population mOS: daraxonrasib 13.2 months / chemotherapy 6.6 months
Overall population mOS: daraxonrasib 13.2 months / chemotherapy 6.7 months RAS G12 population mPFS: daraxonrasib 7.3 months / chemotherapy 3.5 months
Overall population PFS: daraxonrasib 7.2 months / chemotherapy 3.6 months > Thus the treatment had provided them a median life extension of about 3/4 years. The lucky ones probably have got more than an extra year. The 'median' patient in this trial lived ~6.6m longer if they received daraxonrasib. It's worth noting that the performance of the chemotherapy arms was stronger in this trial than previous trials of second-line chemotherapy; whether this reflects better care or a prognostically-superior trial population remains to be seen. |
|
I have quoted exactly the numbers that were written in the abstract of the article yesterday, at the same link that you have used.
What is very weird is that the abstract of the article has been changed, and now it is as you say.
So the numbers from today are worse than those from yesterday.
Perhaps the abstract of yesterday corresponded with a preliminary version of the study report, but meanwhile more patients have died, which has been taken into account in the final version, lowering both the median values for overall survival and for progression-free survival.